tbuckley/cabot-search huggingface dataset:
<i>JAMA Oncology</i>—The Year in Review, 2020
Authors: Mary L. (Nora) Disis
Journal: JAMA Oncology (2021)

2020 has been an unprecedented year, not only for the world but also for JAMA Oncology.The coronavirus disease 2019 (COVID-19) pandemic dominated both the news and the medical literature.JAMA Oncology received more than 350 manuscripts related to the COVID-19 pandemic in 2020, including one of the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in patients with cancer from Wuhan province, China, which was published on March 25, 2020 (Table ). [1]][3][4][5][6] I thank our authors, reviewers, and readers for the significant contributions made to the journal this past year, especially surrounding the pandemic.The editorial board, our JAMA Oncology editors, and I are honored to have the opportunity to serve the oncology community by offering original, innovative, and timely scientific content that has a direct impact on researchers, clinicians, and the patients we serve.Most importantly, we rapidly evaluated and published COVID-19related articles to provide needed information for decisionmaking concerning the infection and its implications in patients with cancer and cancer treatment changes during the pandemic.The journal's impact factor of 24.8 places it as one of the highest-ranking oncology journals.Evaluating and selecting the best manuscripts for publication in the journal was rewarding but challenging.JAMA Oncology received a total of 3777 manuscript submissions in 2020.These submissions included 2967 Original Investigations and 115 Reviews.In 2020, we published 412 total articles, including 102 Original Investigations, 23 Brief Reports, 39 Research Letters, 12 Reviews, 46 Viewpoints, and 1 Special Communication.I would like to thank our authors for choosing to submit their articles to JAMA Oncology.The quality of their published articles is reflected in the more than 4.6 million views they received in 2020.In 2020, the overall acceptance rate was 11%.The acceptance rate for Original Investigations was 6%.We accepted 15% of Review articles, 11.6% of submitted Research Letters, 19% of Viewpoints, and 11.6% of Clinical Challenges.JAMA Oncology is indexed in PubMed/MEDLINE, Web of Science, Scopus, and other databases.More detailed statistics about the journal's content are displayed in the Table.We are also very grateful to our global consortium of peer reviewers who contributed to the journal this year.I am pleased to acknowledge their contribution to JAMA Oncology by publishing the names of the 826 experts who completed a manuscript review in 2020. 7 This group of renowned laboratory, clinical, quantitative, and statistical scientists rapidly provided comprehensive reviews of the submitted manuscripts.
Transient Reduction of Transferrin Saturation Contributes to Hepcidin Inhibition Independently of Erfe in Mice Treated with Erythropoietin
Authors: Irene Artuso, Antonella Nai, Mariateresa Pettinato, Alessia Pagani, Chloe Latour, Benjamin Billore, Maria Rosa Lidonnici, Giacomo Mandelli, Giuliana Ferrari, Clara Camaschella, Leon C. Kautz, Laura Silvestri
Journal: Blood (2017)
HSR21-076: Valued Outcomes in the Cancer Experience (VOICE™): Developing and Validating a Measure of Patient Experience
Authors: Alexandra K. Zaleta, Erica E. Fortune, Melissa F. Miller, Branlyn W. DeRosa, Joanne S. Buzaglo, Karen Hurley, Mitch Golant, Sara Goldberger, Bruce Rapkin, Lillie D. Shockney, Jemeille Ackourey, Kelly A. Clark
Journal: Journal of the National Comprehensive Cancer Network (2021)
CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing
Authors: Peng Shen, Taoyue Yang, Qun Chen, Hao Yuan, Pengfei Wu, Baobao Cai, Lingdong Meng, Xumin Huang, Jiaye Liu, Yihan Zhang, Weikang Hu, Yi Miao, Zipeng Lu, Kuirong Jiang
Journal: Molecular Cancer (2021)

Abstract Background A growing number of studies have focused on investigating circRNAs as crucial regulators in the progression of multiple cancer types. Nevertheless, the biological effects and underlying mechanisms of circRNAs in pancreatic ductal adenocarcinoma (PDAC) remain unclear. Methods Differentially expressed circRNAs between cancerous tissue and adjacent normal tissues were identified by RNA sequencing in PDAC. Subsequently, in vitro and in vivo functional experiments were performed to investigate the functional roles of circNEIL3 in PDAC tumour growth and metastasis. Furthermore, RNA pull-down, dual-luciferase reporter assays, RNA immunoprecipitation (RIP) assays, fluorescent in situ hybridization (FISH) and Sanger sequencing assays were performed to examine the circular interaction among circNEIL3, miR-432-5p and adenosine deaminases acting on RNA 1 (ADAR1). Results CircNEIL3 was upregulated in PDAC and promoted the progression of PDAC cells both in vitro and in vivo. Mechanistically, circNEIL3 was shown to regulate the expression of ADAR1 by sponging miR-432-5p to induce RNA editing of glioma-associated oncogene 1 (GLI1), ultimately influencing cell cycle progression and promoting epithelial-to-mesenchymal transition (EMT) in PDAC cells. Moreover, we discovered that the circNEIL3/miR-432-5p/ADAR1 axis was correlated with the PDAC clinical stage and overall survival of PDAC patients, while ADAR1 may reduce the biogenesis of circNEIL3. Conclusions Our findings reveal that circNEIL3 facilitates the proliferation and metastasis of PDAC through the circNEIL3/miR-432-5p/ADAR1/GLI1/cell cycle and EMT axis and that its expression is regulated by ADAR1 through a negative feedback loop. Therefore, circNEIL3 may serve as a prognostic marker and a therapeutic target for PDAC.
P08.01 Prognostic Impact of Second Predominant Pattern in Lung Adenocarcinoma: Analysis From a Large Multicentric European Database
Authors: P. Bertoglio, L. Ventura, V. Aprile, M. Cattoni, D. Nachira, F. Lococo, M. Rodriguez, F. Guerrera, F. Minervini, L. Gnetti, D. Bacchin, F. Franzi, G. Querzoli, G. Rindi, S. Bellafiore, F. Femia, A. Viti, P. Kestenholz, E. Ruffini, M. Paci, S. Margaritora, A. Imperatori, M. Lucchi, L. Ampollini, A. Terzi
Journal: Journal of Thoracic Oncology (2021)
Evaluation of Hypokalemia
Authors: Morgan E. Grams, Melanie P. Hoenig, Ewout J. Hoorn
Journal: JAMA (2021)

This case report describes the evaluation of a 52-year-old woman taking a thiazide diuretic with hypokalemia (potassium, 2.6 mEq/L) and hypertension (blood pressure, 159/94 mm Hg) and presents an algorithm for the diagnosis and management of underlying causes of low serum potassium levels.
Abstract 15555: Potential Cure for Hypertension? The Effect of Crispr Genome Editing
Authors: Hualing Sun, Conrad Hodgkinson, Richard E Pratt, Victor J Dzau
Journal: Circulation (2020)

Hypertension is recognized as one of the largest contributors to the global burden of disease. Unfortunately, for the majority of patients, hypertension is poorly controlled due, in part, to poor medical compliance resulting from the need to take one or more drugs, often several times daily. An ideal therapy would be administered a single time but yield long-term blood pressure control. Under the appropriate condition, we hypothesize that this modality could potentially lead to a cure for hypertension. In this study, we investigated whether that sustained, and possibly life-long, reductions in blood pressure could be achieved via Crispr-Cas9 mediated disruption of a key gene in the RAAS, Angiotensinogen (AGT). In vitro, we demonstrated that expression of Crispr-Cas9 system in the BRL 3A rat liver cell line led to a significant reduction in AGT protein levels (75% reduction, N=3, P&lt;0.01). Delivery of the Crispr-Cas9 system into the liver via systemic delivery of the hepatocyte-targeting AAV8 reduced both AGT mRNA (70% reduction, N=5, P&lt;0.01) and circulating AGT protein (50% reduction, N=5, P&lt;0.01) and Ang II levels (33% reduction, n=5, P&lt;0.01). In the SHR model of hypertension, Crispr-Cas9 mediated loss of AGT expression reduced systolic blood pressure in adult animals with established hypertension (30-35mmHg decrease in both females and males, N=12, P&lt;0.001). Importantly, AGT gene disruption also prevented the spontaneous development of hypertension in young pre-hypertensive SHR (SHR control: 55-60mmHg increase in systolic blood pressure both female and male SHR; SHR plus Crispr-Cas9: 30-33 mmHg increase. N=12. P&lt;0.001). Importantly, in all the models studied, reductions in blood pressure were sustained for at least 4 months. Importantly, the partial disruption of the hepatic AGT gene was sufficient to control hypertension but did not block the renin-angiotensin response to cardiovascular stress such as sodium depletion. In summary, we have demonstrated that targeting the Crispr-Cas9 system to RAAS reduces blood pressure and may be a potential therapy to achieve safe and sustained, possibly life-long, control of hypertension and this approach maybe a cure for hypertension.
Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
Authors: J. Randall Patrinely, Rebecca Johnson, Aleigha R. Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova, Hui Ling Yeoh, Marisa Palmeri, Fei Ye, Run Fan, Elizabeth J. Davis, Suthee Rapisuwon, Georgina V. Long, Andrew Haydon, Iman Osman, Janice M. Mehnert, Matteo S. Carlino, Ryan J. Sullivan, Alexander M. Menzies, Douglas B. Johnson
Journal: JAMA Oncology (2021)

Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not been well defined.To determine the incidence, time course, spectrum, and associations of chronic irAEs arising from adjuvant anti-PD-1 therapy.This retrospective multicenter cohort study was conducted between 2015 and 2020 across 8 academic medical centers in the United States and Australia. Patients with stage III to IV melanomas treated with anti-PD-1 in the adjuvant setting were included.Incidence, types, and time course of chronic irAEs (defined as irAEs persisting at least 12 weeks after therapy cessation).Among 387 patients, the median (range) age was 63 (17-88) years, and 235 (60.7%) were male. Of these patients, 267 (69.0%) had any acute irAE, defined as those arising during treatment with anti-PD-1, including 52 (19.5%) with grades 3 through 5 events; 1 patient each had fatal myocarditis and neurotoxicity. Chronic irAEs, defined as those that persisted beyond 12 weeks of anti-PD-1 discontinuation, developed in 167 (43.2%) patients, of which most (n = 161; 96.4%) were mild (grade 1 or 2) and most persisted until last available follow-up (n = 143; 85.6%). Endocrinopathies (73 of 88; 83.0%), arthritis (22 of 45; 48.9%), xerostomia (9 of 17; 52.9%), neurotoxicities (11 of 15; 73.3%), and ocular events (5 of 8; 62.5%) were particularly likely to become chronic. In contrast, irAEs affecting visceral organs (liver, colon, lungs, kidneys) had much lower rates of becoming chronic irAEs; for example, colitis became chronic in 6 of 44 (13.6%) cases, of which 4 of 6 (66.7%) resolved with prolonged follow-up. Age, gender, time of onset, and need for steroids were not associated with the likelihood of chronicity of irAEs.In this multicenter cohort study, chronic irAEs associated with anti-PD-1 therapy appear to be more common than previously recognized and frequently persisted even with prolonged follow-up, although most were low grade. The risks of chronic irAEs should be integrated into treatment decision-making.
RNA-based therapies: A cog in the wheel of lung cancer defense
Authors: Parvez Khan, Jawed Akhtar Siddiqui, Imayavaramban Lakshmanan, Apar Kishor Ganti, Ravi Salgia, Maneesh Jain, Surinder Kumar Batra, Mohd Wasim Nasser
Journal: Molecular Cancer (2021)

Abstract Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.
VE-cadherin cleavage in sleep apnoea: new insights into intermittent hypoxia-related endothelial permeability
Authors: Olfa Harki, Renaud Tamisier, Jean-Louis Pépin, Sébastien Bailly, Anissa Mahmani, Brigitte Gonthier, Aude Salomon, Isabelle Vilgrain, Gilles Faury, Anne Briançon-Marjollet
Journal: European Respiratory Journal (2021)

Obstructive sleep apnoea (OSA) causes intermittent hypoxia that in turn induces endothelial dysfunction and atherosclerosis progression. We hypothesised that VE-cadherin cleavage, detected by its released extracellular fragment solubilised in the blood (sVE), may be an early indicator of emergent abnormal endothelial permeability. Our aim was to assess VE-cadherin cleavage in OSA patients and in in vivo and in vitro intermittent hypoxia models to decipher the cellular mechanisms and consequences.Sera from seven healthy volunteers exposed to 14 nights of intermittent hypoxia, 43 OSA patients and 31 healthy control subjects were analysed for their sVE content. Human aortic endothelial cells (HAECs) were exposed to 6 h of intermittent hypoxia in vitro, with or without an antioxidant or inhibitors of hypoxia-inducible factor (HIF)-1, tyrosine kinases or vascular endothelial growth factor (VEGF) pathways. VE-cadherin cleavage and phosphorylation were evaluated, and endothelial permeability was assessed by measuring transendothelial electrical resistance (TEER) and fluorescein isothiocyanate (FITC)-dextran flux.sVE was significantly elevated in sera from healthy volunteers submitted to intermittent hypoxia and OSA patients before treatment, but conversely decreased in OSA patients after 6 months of continuous positive airway pressure treatment. OSA was the main factor accounting for sVE variations in a multivariate analysis. In in vitro experiments, cleavage and expression of VE-cadherin increased upon HAEC exposure to intermittent hypoxia. TEER decreased and FITC-dextran flux increased. These effects were reversed by all of the pharmacological inhibitors tested.We suggest that in OSA, intermittent hypoxia increases endothelial permeability in OSA by inducing VE-cadherin cleavage through reactive oxygen species production, and activation of HIF-1, VEGF and tyrosine kinase pathways.
Abstract 1683: Impact of Microvascular Injury on Long-Term Mortality After Primary Coronary Intervention for Acute Myocardial Infarction
Authors: Koichi Tamita, Takashi Akasaka, Atsuhi Yamamuro, Syuichiro Kaji, Minako Katayama, Kazuaki Tanabe, Tomoko Tani, Makoto Kinoshita, Takeshi Kitai, Takafumi Yamane, Yasuki Kihara
Journal: Circulation (2007)

Background: Recent studies have shown that severe microvascular injury can be assessed from coronary flow velocity (CFV) pattern by using a Doppler guidewire in patients with acute myocardial infar...
Abstract 11924: Modern Breast Cancer Treatment With Anthracycline Containing Chemotherapy Improved the Incidence of Heart Failure
Authors: Yoshitoshi Urabe, Kenichi Arimura, Hiroshi Kojima, Aya Watanabe, Masaki Ikeuchi
Journal: Circulation (2018)

Background: Modern cancer treatment improved patient outcomes dramatically. In the treatment of breast cancer, the anthracyclines are key components of many chemotherapies. However, with prolong su...
Accuracy Requirements for Cost-effective Suicide Risk Prediction Among Primary Care Patients in the US
Authors: Eric L. Ross, Kelly L. Zuromski, Ben Y. Reis, Matthew K. Nock, Ronald C. Kessler, Jordan W. Smoller
Journal: JAMA Psychiatry (2021)

<h3>Importance</h3> Several statistical models for predicting suicide risk have been developed, but how accurate such models must be to warrant implementation in clinical practice is not known. <h3>Objective</h3> To identify threshold values of sensitivity, specificity, and positive predictive value that a suicide risk prediction method must attain to cost-effectively target a suicide risk reduction intervention to high-risk individuals. <h3>Design, Setting, and Participants</h3> This economic evaluation incorporated published data on suicide epidemiology, the health care and societal costs of suicide, and the costs and efficacy of suicide risk reduction interventions into a novel decision analytic model. The model projected suicide-related health economic outcomes over a lifetime horizon among a population of US adults with a primary care physician. Data analysis was performed from September 19, 2019, to July 5, 2020. <h3>Interventions</h3> Two possible interventions were delivered to individuals at high predicted risk: active contact and follow-up (ACF; relative risk of suicide attempt, 0.83; annual health care cost, $96) and cognitive behavioral therapy (CBT; relative risk of suicide attempt, 0.47; annual health care cost, $1088). <h3>Main Outcomes and Measures</h3> Fatal and nonfatal suicide attempts, quality-adjusted life-years (QALYs), health care sector costs and societal costs (in 2016 US dollars), and incremental cost-effectiveness ratios (ICERs) (with ICERs ≤$150 000 per QALY designated cost-effective). <h3>Results</h3> With a specificity of 95% and a sensitivity of 25%, primary care–based suicide risk prediction could reduce suicide death rates by 0.5 per 100 000 person-years (if used to target ACF) or 1.6 per 100 000 person-years (if used to target CBT) from a baseline of 15.3 per 100 000 person-years. To be cost-effective from a health care sector perspective at a specificity of 95%, a risk prediction method would need to have a sensitivity of 17.0% or greater (95% CI, 7.4%-37.3%) if used to target ACF and 35.7% or greater (95% CI, 23.1%-60.3%) if used to target CBT. To achieve cost-effectiveness, ACF required positive predictive values of 0.8% for predicting suicide attempt and 0.07% for predicting suicide death; CBT required values of 1.7% for suicide attempt and 0.2% for suicide death. <h3>Conclusions and Relevance</h3> These findings suggest that with sufficient accuracy, statistical suicide risk prediction models can provide good health economic value in the US. Several existing suicide risk prediction models exceed the accuracy thresholds identified in this analysis and thus may warrant pilot implementation in US health care systems.
P69.01 Real-World Data of EGFR-TKI Treatment Sequence in Non-Small Cell Lung Cancer Patients in Japan
Authors: K. Ito, K. Matsumura, K. Togo, H. Kikkawa, B. Li, J. Ivanova, M. Pastel, H. Kenmotsu
Journal: Journal of Thoracic Oncology (2021)
3D-bioprinting ready-to-implant anisotropic menisci recapitulate healthy meniscus phenotype and prevent secondary joint degeneration
Authors: Ye Sun, Yuxin Zhang, Qiang Wu, Feng Gao, Yongzhong Wei, Yimin Ma, Wenbo Jiang, Kerong Dai
Journal: Theranostics (2021)

Objectives: Disruption of anisotropic phenotypes of the meniscus would contribute to OA progression. Exploring phenotype changes of the anisotropic meniscus in joint degeneration would help understand the biologic interaction between the meniscus and OA, and further facilitate the therapeutic strategies of meniscus injury-related joint degeneration. Meanwhile, engineering biomimetic meniscal tissue mimicking the anisotropy of the healthy meniscus remains a challenge. Methods & Results: Meniscal disruption of phenotype anisotropy (PBV growth, cellular phenotype and ECM depositions) was confirmed in OA patient samples. To recapitulate healthy meniscus phenotypes, 3D-bioprinted anisotropic TCM meniscus constructs with PBV growth and regional differential cell and ECM depositions were generated. Transplanted 3D-bioprinted meniscus into rabbit knees recapitulated phenotypes of native healthy meniscus and conferred long-term protection against secondary joint degeneration. Conclusion: 3D-bioprinted TCM meniscus not only restored the anisotropy of native healthy meniscus with PBV infiltration and better shape retention, but better maintained joint function and prevented secondary joint degeneration, which provided a new strategy for the clinical treatment of meniscus injury-related joint degenerative diseases.
Screening for Hearing Loss in Older Adults
Authors: Alex H. Krist, Karina W. Davidson, Carol M. Mangione, Michael Cabana, Aaron B. Caughey, Esa M. Davis, Katrina E. Donahue, Chyke A. Doubeni, John W. Epling, Martha Kubik, Li Li, Gbenga Ogedegbe, Lori Pbert, Michael Silverstein, James Stevermer, Chien-Wen Tseng, John B. Wong
Journal: JAMA (2021)

<h3>Importance</h3> Age-related sensorineural hearing loss is a common health problem among adults. Nearly 16% of US adults 18 years or older report difficulty hearing. The prevalence of perceived hearing loss increases with age. Hearing loss can adversely affect an individual's quality of life and ability to function independently and has been associated with increased risk of falls, hospitalizations, social isolation, and cognitive decline. <h3>Objective</h3> To update its 2012 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on screening for hearing loss in adults 50 years or older. <h3>Population</h3> Asymptomatic adults 50 years or older with age-related hearing loss. <h3>Evidence Assessment</h3> Because of a lack of evidence, the USPSTF concludes that the benefits and harms of screening for hearing loss in asymptomatic older adults are uncertain and that the balance of benefits and harms cannot be determined. More research is needed. <h3>Recommendation</h3> The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for hearing loss in older adults. (I statement)
Distant Lymph Node Metastases From Breast Cancer—Is it Time to Review TNM Cancer Staging?
Authors: Yutian Zou, Xiaoqian Hu, Xinpei Deng
Journal: JAMA Network Open (2021)

Hong Pan, MD, PhD; Hui Wang, MS; Mengjia Qian, MS; Xinrui Mao, MS; Guojian Shi, MS; Ge Ma, MD; Muxin Yu, MD; Hui Xie, MD; Lijun Ling, MD, PhD; Qiang Ding, MD, PhD; Kai Zhang, MS; Shui Wang, MD, PhD; Wenbin Zhou, MD, PhD
P25.07 Nutritional Risk Status Predicts Outcomes of Mexican Patients with Malignant Pleural Mesothelioma
Authors: S. Campos-Gomez, J. Esquivel-Gutierrez, J.J. Valdéz-Andrade, E. Jaimes Alpizar, G. Pacheco-Cuellar, H. Ramírez, K. Campos-Gomez
Journal: Journal of Thoracic Oncology (2021)
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Authors: Roland B. Walter, Yishai Ofran, Agnieszka Wierzbowska, Farhad Ravandi, Christopher S. Hourigan, Lok Lam Ngai, Adriano Venditti, Francesco Buccisano, Gert J. Ossenkoppele, Gail J. Roboz
Journal: Leukemia (2021)
P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
Authors: B.C. Cho, Z. Piotrowska, X. Le, S.B. Goldberg, J. Goldman, A. De Langen, I. Okamoto, P. Smith, I. Mensi, J. Maidment, R. Hartmaier, M. Li, G. Doughton, G. Patel, J. Pease, P. Szekeres, J. Riess, H. Yu
Journal: Journal of Thoracic Oncology (2021)